UroGen Pharma Ltd.(URGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,479 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
URGN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for UroGen Pharma Ltd. (URGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores URGN at 30.7/100 on a 32-signal composite quality model, placing it at rank #2,479 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), UroGen Pharma Ltd. reports quarterly revenue of $72.5M, net income of $-14.4M, free cash flow of $-33.1M. Top institutional holders of URGN by reported 13-F value include RTW INVESTMENTS, BlackRock, MORGAN STANLEY, based on the most recent SEC filings. URGN trades on the Nasdaq exchange and files with the SEC under CIK 1668243. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate URGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UroGen Pharma Ltd. directly from SEC EDGAR. UroGen Pharma Ltd.'s 13F Pro composite quality score has ranged between 4 and 31 since 2021, currently 30.7 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$72.5M
Net Income
Q2 2026
$-14.4M
Free Cash Flow
Q2 2026
$-33.1M
ROIC
Q2 2026
0.7%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+21.4% YoYNet Income
-21.0% YoYOperating Income
-29.0% YoYTotal Assets
-29.8% YoYTotal Debt
+2.7% YoYOp. Cash Flow
-67.9% YoYFree Cash Flow
-67.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $109.8M +21.4% | $90.4M +9.3% | $82.7M +28.5% | $64.4M +34.0% | $48.0M +307.2% | $11.8M |
| Net Income | $-153.5M -21.0% | $-126.9M -24.1% | $-102.2M +6.9% | $-109.8M +0.9% | $-110.8M +13.7% | $-128.5M |
| Operating Income | $-124.9M -29.0% | $-96.8M -47.7% | $-65.5M +17.1% | $-79.0M +14.4% | $-92.3M +27.2% | $-126.7M |
| Total Assets | $200.5M -29.8% | $285.7M +60.2% | $178.3M +31.5% | $135.6M +13.3% | $119.7M -1.9% | $122.0M |
| Total Debt | $125.0M +2.7% | $121.7M +23.5% | $98.6M +1.0% | $97.5M | $0.00 | — |
| Operating Cash Flow | $-162.4M -67.9% | $-96.8M -26.7% | $-76.4M +12.8% | $-87.6M -3.1% | $-84.9M +19.8% | $-105.9M |
| Free Cash Flow | $-162.7M -67.7% | $-97.1M -26.8% | $-76.6M +12.8% | $-87.8M -2.5% | $-85.6M +20.0% | $-107.1M |
Get alerted when URGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for UroGen Pharma Ltd. including:
Top Institutional Holders of URGN
RTW INVESTMENTS, LP
$167.2M4,543,895 shBlackRock, Inc.
$117.8M3,201,461 shMORGAN STANLEY
$94.8M2,576,363 shKynam Capital Management, LP
$89.6M2,434,207 shLEUCADIA NATIONAL CORP
$80.9M2,199,652 shSG Americas Securities, LLC
$75.5M2,052,906 shAMERICAN CENTURY COMPANIES INC
$62.0M1,685,719 shACORN CAPITAL ADVISORS, LLC
$61.6M1,673,420 shPoint72 Asset Management, L.P.
$56.1M1,525,549 shFRONTIER CAPITAL MANAGEMENT CO LLC
$55.5M1,508,547 sh
| Fund | Value | Shares |
|---|---|---|
| RTW INVESTMENTS, LP | $167.2M | 4,543,895 |
| BlackRock, Inc. | $117.8M | 3,201,461 |
| MORGAN STANLEY | $94.8M | 2,576,363 |
| Kynam Capital Management, LP | $89.6M | 2,434,207 |
| LEUCADIA NATIONAL CORP | $80.9M | 2,199,652 |
| SG Americas Securities, LLC | $75.5M | 2,052,906 |
| AMERICAN CENTURY COMPANIES INC | $62.0M | 1,685,719 |
| ACORN CAPITAL ADVISORS, LLC | $61.6M | 1,673,420 |
| Point72 Asset Management, L.P. | $56.1M | 1,525,549 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $55.5M | 1,508,547 |
Companies Similar to URGN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Syndax Pharmaceuticals Inc
Ovid Therapeutics Inc.
Viridian Therapeutics, Inc.\DE
CG Oncology, Inc.
REGENXBIO Inc.
AGIOS PHARMACEUTICALS, INC.
BICYCLE THERAPEUTICS PLC
Foghorn Therapeutics Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put URGN on your watchlist
Track score changes the day UroGen Pharma Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is URGN a good stock to buy?
13F Pro's AI-powered analysis of UroGen Pharma Ltd. (URGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for URGN are available on the URGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. URGN is classified as a mid company.
Which hedge funds own URGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling URGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of UroGen Pharma Ltd.'s investment landscape.